HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 244 filers reported holding HAEMONETICS CORP in Q2 2022. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $13,483 | -99.9% | 171,426 | -0.3% | 0.05% | 0.0% |
Q3 2022 | $12,735,000 | -6.4% | 172,021 | -17.6% | 0.05% | -2.0% |
Q2 2022 | $13,607,000 | -21.4% | 208,758 | -23.7% | 0.05% | +4.2% |
Q1 2022 | $17,303,000 | +50.0% | 273,696 | +25.8% | 0.05% | +45.5% |
Q4 2021 | $11,537,000 | +338.2% | 217,513 | +483.1% | 0.03% | +312.5% |
Q3 2021 | $2,633,000 | -93.6% | 37,306 | -93.9% | 0.01% | -94.2% |
Q2 2021 | $40,836,000 | +173.4% | 612,780 | +355.4% | 0.14% | +127.9% |
Q1 2021 | $14,939,000 | +6599.1% | 134,573 | +7050.5% | 0.06% | +6000.0% |
Q4 2020 | $223,000 | -82.6% | 1,882 | -87.2% | 0.00% | -85.7% |
Q3 2020 | $1,279,000 | -92.1% | 14,658 | -91.9% | 0.01% | -93.3% |
Q2 2020 | $16,152,000 | +397.6% | 180,352 | +538.3% | 0.10% | +420.0% |
Q4 2019 | $3,246,000 | +185.5% | 28,255 | +148.5% | 0.02% | +53.8% |
Q4 2018 | $1,137,000 | -85.1% | 11,368 | -89.1% | 0.01% | -86.9% |
Q1 2018 | $7,625,000 | +96.6% | 104,218 | +56.1% | 0.10% | +147.5% |
Q4 2017 | $3,879,000 | – | 66,780 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |